|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
DK261490D0
(da)
|
1990-10-31 |
1990-10-31 |
Novo Nordisk As |
New pharmaceutical compound
|
|
US6165467A
(en)
|
1991-07-20 |
2000-12-26 |
Yoshihide Hagiwara |
Stabilized human monoclonal antibody preparation
|
|
US5789192A
(en)
|
1992-12-10 |
1998-08-04 |
Schering Corporation |
Mammalian receptors for interleukin-10 (IL-10)
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JP3681206B2
(ja)
|
1995-12-26 |
2005-08-10 |
株式会社三菱化学ヤトロン |
抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
|
|
US6084248A
(en)
|
1996-06-28 |
2000-07-04 |
Seiko Epson Corporation |
Thin film transistor, manufacturing method thereof, and circuit and liquid crystal display device using the thin film transistor
|
|
EP2065396A1
(en)
|
1996-08-30 |
2009-06-03 |
Human Genome Sciences, Inc. |
Interleukin-19
|
|
US5985614A
(en)
|
1996-08-30 |
1999-11-16 |
Human Genome Sciences, Inc. |
Polynucleotides encoding interleukin-19
|
|
WO1999046281A2
(en)
|
1998-03-10 |
1999-09-16 |
Genentech, Inc. |
Novel polypeptides and nucleic acids encoding the same
|
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
|
WO1998048837A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
|
WO1999003982A1
(en)
|
1997-07-16 |
1999-01-28 |
Human Genome Sciences, Inc. |
Interleukin-20
|
|
US6486301B1
(en)
|
1997-07-16 |
2002-11-26 |
Human Genome Sciences, Inc. |
Interleukin-20
|
|
JP2001512668A
(ja)
|
1997-08-06 |
2001-08-28 |
ザイモジェネティクス，インコーポレイティド |
リポカリン相同体
|
|
US6576743B1
(en)
|
1997-11-26 |
2003-06-10 |
Zymogenetics, Inc. |
Mammalian cytokine-like polypeptide-10
|
|
PT1047781E
(pt)
|
1998-01-23 |
2004-11-30 |
Immunex Corp |
Receptores de il-18
|
|
CA2323236A1
(en)
|
1998-03-09 |
1999-09-16 |
Schering Corporation |
Human receptor proteins; related reagents and methods
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
CN1233476A
(zh)
|
1998-04-24 |
1999-11-03 |
陆道培 |
治疗急性白血病的药物及其制备方法
|
|
WO1999061630A2
(en)
|
1998-05-26 |
1999-12-02 |
Regeneron Pharmaceuticals, Inc. |
Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
|
|
AU4411699A
(en)
|
1998-06-05 |
1999-12-20 |
Human Genome Sciences, Inc. |
Interferon receptor hkaef92
|
|
US7034123B2
(en)
|
1998-09-01 |
2006-04-25 |
Genetech, Inc. |
Anti-PRO1347 antibodies
|
|
JP2002524514A
(ja)
*
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
|
US6451286B1
(en)
*
|
1998-12-21 |
2002-09-17 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
|
|
EP1141008A1
(en)
|
1998-12-31 |
2001-10-10 |
Millennium Pharmaceuticals, Inc. |
Class ii cytokine receptor-like proteins and nucleic acids encoding them
|
|
JP2004522402A
(ja)
|
1999-06-02 |
2004-07-29 |
ジェネンテック・インコーポレーテッド |
同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
|
|
US20050060101A1
(en)
|
1999-06-28 |
2005-03-17 |
Bevilacqua Michael P. |
Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
|
|
WO2001024814A1
(en)
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
|
KR100399156B1
(ko)
*
|
1999-11-19 |
2003-09-26 |
주식회사 엘지생명과학 |
α-인터페론의 용액제형
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
EP1246846B1
(en)
|
1999-12-23 |
2008-09-10 |
ZymoGenetics, Inc. |
Soluble interleukin-20 receptor
|
|
AU2001251336B2
(en)
|
2000-04-07 |
2006-09-14 |
Signal Coordinating Therapy, Inc. |
Methods and compositions for treating neoplasms
|
|
US7015194B2
(en)
|
2000-05-10 |
2006-03-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising factor VIIa and anti-TFPI
|
|
JP5490972B2
(ja)
|
2000-08-04 |
2014-05-14 |
中外製薬株式会社 |
タンパク質注射製剤
|
|
CA2418950A1
(en)
|
2000-08-08 |
2002-02-14 |
Zymogenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
|
ES2644275T3
(es)
|
2000-08-11 |
2017-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Preparaciones estabilizadas que contienen anticuerpos
|
|
US6875432B2
(en)
|
2000-10-12 |
2005-04-05 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US7101539B2
(en)
|
2001-02-28 |
2006-09-05 |
Eli Lilly And Company |
Use of LP82 to treat hematopoietic disorders
|
|
ATE432942T1
(de)
|
2001-03-09 |
2009-06-15 |
Zymogenetics Inc |
Löslicher heterodimerer cytokinrezeptor
|
|
ATE454137T1
(de)
|
2001-07-25 |
2010-01-15 |
Facet Biotech Corp |
Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
|
|
WO2003028630A2
(en)
|
2001-10-04 |
2003-04-10 |
Genetics Institute Llc. |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US7022289B1
(en)
|
2001-10-10 |
2006-04-04 |
The United States Of America As Represented By The Secretary Of The Army |
Chemical and biological sampling device and kit and method of use thereof
|
|
IL161968A0
(en)
*
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
|
ATE521361T1
(de)
|
2001-12-17 |
2011-09-15 |
Zymogenetics Inc |
Verfahren zur behandlung von gebärmutterhalskrebs
|
|
JP3792698B2
(ja)
|
2002-02-14 |
2006-07-05 |
中外製薬株式会社 |
抗体含有溶液製剤
|
|
DE60322513D1
(de)
|
2002-02-27 |
2008-09-11 |
Immunex Corp |
Stabilisierte TNFR-Fc Formulierung mit Arginin
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
US20040009168A1
(en)
|
2002-04-05 |
2004-01-15 |
Elizabet Kaisheva |
Multidose antibody formulation
|
|
AU2005254062B2
(en)
|
2002-04-11 |
2011-02-17 |
Medimmune, Llc |
High pressure spray-dry of bioactive materials
|
|
PT1531850E
(pt)
|
2002-06-07 |
2012-05-07 |
Zymogenetics Inc |
Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
CA2490423A1
(en)
|
2002-06-21 |
2003-12-31 |
Biogen Idec Inc. |
Buffered formulations for concentrating antibodies and methods of use thereof
|
|
ES2271610T3
(es)
|
2002-07-18 |
2007-04-16 |
Fabio Perini S.P.A. |
Unidad de almacenamiento para productos alargados.
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
PT2236154T
(pt)
|
2003-02-10 |
2018-06-26 |
Biogen Ma Inc |
Formulação de imunoglobulinas e método de preparação das mesmas
|
|
ES2349779T5
(es)
*
|
2003-04-04 |
2013-11-26 |
Genentech, Inc. |
Formulaciones de anticuerpos y de proteínas a concentración elevada
|
|
EP1648509B8
(en)
|
2003-07-15 |
2012-10-24 |
Amgen Inc. |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
|
HUE026793T2
(en)
|
2003-10-01 |
2016-07-28 |
Kyowa Hakko Kirin Co Ltd |
A method for stabilizing an antibody and a stabilized solution-type antibody preparation
|
|
EP1712240B1
(en)
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stable water-based medicinal preparation containing antibody
|
|
DK1812476T3
(da)
|
2004-10-22 |
2010-10-25 |
Zymogenetics Inc |
Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
|
|
JP2008532931A
(ja)
|
2005-02-08 |
2008-08-21 |
ザイモジェネティクス， インコーポレイテッド |
抗ｉｌ−２０、抗ｉｌ−２２および抗ｉｌ−２２ｒａ抗体ならびに結合パートナー、ならびに炎症における使用法
|
|
US7525604B2
(en)
|
2005-03-15 |
2009-04-28 |
Naxellent, Llc |
Windows with electrically controllable transmission and reflection
|
|
ATE501248T1
(de)
|
2005-07-02 |
2011-03-15 |
Arecor Ltd |
Stabile wässrige systeme mit proteinen
|
|
WO2007006858A2
(en)
|
2005-07-12 |
2007-01-18 |
Oy Jurilab Ltd |
Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
|
|
CA2618068C
(en)
|
2005-08-05 |
2016-02-16 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
|
EP1945814A2
(en)
|
2005-09-27 |
2008-07-23 |
Source MDX |
Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
|
|
WO2007038501A2
(en)
|
2005-09-27 |
2007-04-05 |
The Feinstein Institute For Medical Research |
Rheumatoid arthritis markers
|
|
CN104984352A
(zh)
|
2005-11-21 |
2015-10-21 |
圣诺菲·帕斯图尔有限公司 |
重组病毒的稳定制剂
|
|
EP1962907A2
(en)
|
2005-12-21 |
2008-09-03 |
Wyeth a Corporation of the State of Delaware |
Protein formulations with reduced viscosity and uses thereof
|
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
|
KR20080098504A
(ko)
|
2006-02-03 |
2008-11-10 |
메디뮨 엘엘씨 |
단백질 제제
|
|
DE102006005094A1
(de)
|
2006-02-04 |
2007-08-09 |
Degussa Gmbh |
Titandioxid und Polycarboxylatether enthaltende Dispersion
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
WO2007105133A2
(en)
|
2006-03-15 |
2007-09-20 |
Koninklijke Philips Electronics N.V. |
Remote control pointing technology with roll detection
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
JP4294082B2
(ja)
|
2006-03-23 |
2009-07-08 |
協和発酵キリン株式会社 |
ヒトトロンボポエチン受容体に対するアゴニスト抗体
|
|
EP1998806A1
(en)
*
|
2006-03-28 |
2008-12-10 |
F. Hoffmann-Roche AG |
Anti-igf-1r human monoclonal antibody formulation
|
|
EP1857559A1
(en)
|
2006-05-16 |
2007-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting responsiveness to TNF alpha blocking agents
|
|
JP2009540015A
(ja)
|
2006-06-14 |
2009-11-19 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
抗ｅｇｆｒ抗体の凍結乾燥製剤
|
|
US20080031882A1
(en)
|
2006-06-19 |
2008-02-07 |
Liang Spencer C |
Methods of modulating IL-22 and IL-17
|
|
ES2531933T3
(es)
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
|
EP2081553B1
(en)
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
EP2076287A2
(en)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
|
WO2008048986A2
(en)
|
2006-10-17 |
2008-04-24 |
Children's Hospital Medical Center |
Gene array technique for predicting response in inflammatory bowel diseases
|
|
CA2668955A1
(en)
|
2006-11-09 |
2008-05-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
|
|
CL2007003583A1
(es)
|
2006-12-11 |
2008-07-18 |
Hoffmann La Roche |
Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
|
|
CL2008000058A1
(es)
*
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
|
|
EP2132343B1
(en)
|
2007-03-01 |
2012-08-29 |
Université Catholique de Louvain |
Method for the determination and the classification of rheumatic conditions
|
|
US8575751B2
(en)
|
2007-03-23 |
2013-11-05 |
Panasonic Corporation |
Conductive bump, method for producing the same, and electronic component mounted structure
|
|
EP2077859A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
ANTIBODY FORMULATION
|
|
GB0707938D0
(en)
|
2007-04-25 |
2007-05-30 |
Univ Strathclyde |
Precipitation stabilising compositions
|
|
WO2008132176A2
(en)
|
2007-04-27 |
2008-11-06 |
Universite Catholique De Louvain |
Method for evaluating the response of an individual to tnf blocking therapy
|
|
US20100303813A1
(en)
|
2007-06-08 |
2010-12-02 |
Biogen Idec Ma Inc. |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
PT2170390T
(pt)
|
2007-06-14 |
2019-02-12 |
Biogen Ma Inc |
Formulações com anticorpo natalizumab
|
|
US20090004189A1
(en)
|
2007-06-18 |
2009-01-01 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
|
AU2008269086B2
(en)
|
2007-06-25 |
2014-06-12 |
Amgen Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
EP2173163A4
(en)
|
2007-07-06 |
2010-12-08 |
Glaxosmithkline Llc |
ANTIBODY FORMULATIONS
|
|
US20110143351A1
(en)
|
2007-07-20 |
2011-06-16 |
National Institute For Biopr0Essing Research And Training Limited |
Glyosylation markers for cancer and chronic inflammation
|
|
WO2009015398A1
(en)
|
2007-07-26 |
2009-01-29 |
Oklahoma Medical Research Foundation |
Methods for inflammatory disease management
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
CA3102679A1
(en)
|
2007-12-14 |
2009-06-25 |
Birgitte Urso |
Antibodies against human nkg2d and uses thereof
|
|
CA2714296A1
(en)
|
2008-02-20 |
2009-08-27 |
G2 Inflammation Pty Ltd |
Humanized anti-c5ar antibodies
|
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
|
CN103396480A
(zh)
|
2008-05-15 |
2013-11-20 |
诺沃—诺迪斯克有限公司 |
抗体纯化方法
|
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
WO2010000721A1
(en)
|
2008-06-30 |
2010-01-07 |
Novo Nordisk A/S |
Anti-human interleukin-20 antibodies
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
JP2012501184A
(ja)
|
2008-08-28 |
2012-01-19 |
ワイス・エルエルシー |
自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
|
|
KR20110047232A
(ko)
|
2008-09-19 |
2011-05-06 |
에프. 호프만-라 로슈 아게 |
신규한 항체 제형
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US8361469B2
(en)
|
2008-12-22 |
2013-01-29 |
Novo Nordisk A/S |
Antibodies against tissue factor pathway inhibitor
|
|
EP2414542B1
(en)
|
2009-03-30 |
2017-08-30 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Methods of predicting clinical course and treating multiple sclerosis
|
|
EP3211094A3
(en)
|
2009-09-03 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
|
US20120208719A1
(en)
|
2009-10-16 |
2012-08-16 |
Mayo Foundation For Medical Education And Research |
Assessing rheumatoid arthritis
|
|
US8580528B2
(en)
|
2009-10-16 |
2013-11-12 |
Stichting Vu-Vumc |
Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
|
|
WO2011104381A2
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
KR20130086144A
(ko)
*
|
2010-05-28 |
2013-07-31 |
노보 노르디스크 에이/에스 |
항체 및 보존제를 포함하는 안정한 다중-투여 조성물
|
|
JP2013529089A
(ja)
|
2010-06-07 |
2013-07-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
インターロイキン−６受容体を阻害するモノクローナル抗体による薬剤治療に対する応答を予測するための遺伝子発現マーカー
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|